Source: Pharmacy Times articles
Banerjee addressed factors to consider when selecting a regimen, the available treatments in this category, and their key differences.
Read More
Recent Content
- Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses
- Cell surface marker heterogeneity in human myeloma cell lines for modeling of disease and therapy
- A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia
- Blenrep-Based Combo Provides Survival Benefit in Relapsed/Refractory Multiple Myeloma
- A systematic literature review on clonal evolution events preceding relapse in multiple myeloma
- Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis
- A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma
- Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial
- Triplet regimen extends OS in relapsed or refractory multiple myeloma
- Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT